AI Insight
A real-world study of nearly 60,000 adults with type 2 diabetes found that those taking semaglutide experienced approximately 15% fewer bone fractures compared to users of other common weight-loss medications, despite achieving greater weight loss. This finding is notable because significant weight loss is typically associated with increased fracture risk due to bone density changes. The research analyzed health records to compare fracture rates between semaglutide users and those taking alternative weight-loss treatments.
Why it matters
This suggests semaglutide may provide dual benefits for people with type 2 diabetes by enabling substantial weight loss while simultaneously protecting bone health, addressing a common concern that weight loss can weaken bones. If confirmed in controlled trials, this could make semaglutide particularly valuable for older adults or those at higher risk of osteoporosis.
A large real-world study suggests semaglutide (Ozempic, Wegovy, Rybelsus) may offer an unexpected bonus for people with type 2 diabetes: stronger protection against bone fractures while delivering greater weight loss. Researchers analyzing health records from nearly 60,000 adults found that people taking semaglutide experienced about 15% fewer fractures than those using other common weight-loss medications, despite losing more weight.
Source: Semaglutide (Ozempic) linked to fewer bone fractures despite greater weight loss